Phase I study assessing SCI-160 for treatment of pain
Latest Information Update: 04 Apr 2022
At a glance
- Drugs SCI-160 (Primary)
- Indications Pain
- Focus Adverse reactions
- Sponsors SciSparc
- 04 Apr 2022 New trial record
- 30 Mar 2022 According to SciSparc media release, the company intends to submit FDA Investigational New Drug (IND) Phase I study application for treatment for pain in 2022